共查询到20条相似文献,搜索用时 15 毫秒
1.
Liver histology in patients with HBsAg negative anti-HBc and anti-HCV positive chronic hepatitis 总被引:1,自引:0,他引:1
Sagnelli E Pasquale G Coppola N Marrocco C Scarano F Imparato M Sagnelli C Scolastico C Piccinino F 《Journal of medical virology》2005,75(2):222-226
The liver histology of 68 consecutive anti-HCV/HCV-RNA positive chronic hepatitis patients who were HBsAg/anti-HBs negative, anti-HBc positive (Case bC group) was compared with that of 68 anti-HCV/HCV-RNA positive chronic hepatitis patients who were HBsAg/anti-HBc negative (control C group). The patients were pair-matched by age (+/-5 years), sex, and risk factors for the acquisition of parenteral infection. Case bC group showed a significantly higher mean fibrosis score (2.3 +/- 1.1) than control C group (1.5 +/- 1.1, P <0.001) and more histological evidence of cirrhosis (22% vs. 7.3%, P <0.05). In addition, the patients in Case bC group showed more severe inflammation of the portal tracts (3.5 +/- 0.8 vs. 3.0 +/- 1.1, P <0.005) and there was a higher prevalence of patients with rhomboid-shaped hepatocytes (26.4% vs. 2.7%, P <0.005), acidophilic bodies (33.8% vs. 1.4%, P <0.0001), sinusoidal inflammation (29.4% vs. 10.3%, P <0.01), lymphoid follicles in the portal tracts (72% vs. 44.1%, P <0.05), Kupffer cell proliferation (29.4% vs. 11.8%, P <0.05), bile duct damage (44.1% vs. 10.3%, P <0.0001), and ductular proliferation (30.9% vs. 2.7%, P <0.001) than in control C group. No difference in these histological features was observed between HBV-DNA negative and positive patients in Case bC group. The data suggest that anti-HBc positive patients with HCV chronic infection have a significantly higher degree of liver fibrosis, and that hepatocellular apoptosis, bile duct damage, and ductular proliferation correlate with the presence of this antibody in the serum. 相似文献
2.
D Villari G Raimondo M A Freni G Rodinò A Aiello A Fava G Longo D Batolo 《Pathology》1992,24(4):243-246
To evaluate the histological effects of alpha Interferon (IFN) therapy, serial liver biopsy specimens from 30 patients with chronic hepatitis were studied. The biopsies were examined using a scoring system. After 12 mths of IFN therapy responders were 8 out of 11 HBV infected patients, 10 out of 12 HCV infected patients and only 1 out of 7 patients with cryptogenetic hepatitis. As spontaneous improvement of hepatic changes is infrequent, our data indicate that in terms of histological patterns interferon therapy is effective in chronic viral hepatitis. 相似文献
3.
4.
Yamada S Suou T Kawasaki H Horie Y Nagami M Yashima S Sugihara C Tanaka H 《Research communications in molecular pathology and pharmacology》1999,104(3):253-263
Hepatic vitronectin expression was assessed in 27 patients with chronic hepatitis C before and after interferon alpha treatment and in 7 control patients. Before interferon therapy, vitronectin was localized in the hepatocytes and in the portal and central venous regions. A high correlation was found for the vitronectin expression level with the histological grading and staging scores in the hepatocytes as well as in the portal region. After interferon therapy, the hepatic vitronectin was significantly decreased in the sustained and transient responders, but it was not as markedly decreased in the nonresponders and the non-treated group. A good correlation was found for the vitronectin expression with the staging scores but not with the grading scores in the portal region. These findings suggest that hepatic vitronectin is influenced by interferon therapy and that it may play an important role as a hepatic adhesion molecule through the improvement of inflammation, necrosis and fibrogenesis. 相似文献
5.
Arase Y Ikeda K Suzuki F Suzuki Y Kobayashi M Akuta N Hosaka T Sezaki H Yatsuji H Kawamura Y Kobayashi M Kumada H 《Journal of medical virology》2007,79(9):1286-1292
The aim of this study was to elucidate the long-term outcome after interferon (IFN) or lamivudine (LMV) treatment in Japanese patients with hepatitis B e antigen (HBeAg) positive chronic hepatitis B. Inclusion criteria were biopsy proven chronic hepatitis or liver cirrhosis, no history of IFN or LMV treatment. Three hundred twenty-seven patients satisfied above criteria were treated with IFN or LMV. The primary end point of our study was serum clearance of HBeAg and decrease of serum HBV-DNA to < or =5 LEG/ml after the initiation of treatment. This study was a retrospective cohort study. Attainment of serum clearance of HBeAg and decrease of serum HBV-DNA to < or =5 LEG/ml was regarded as response. Two hundred eighty-six patients had got response after the initiation of treatment. The cumulative rate of response was 28.0% in the first year, 56.2% at the 5th year and 82.5% at the 10th year. Response occurred when HBV-DNA load was high level of more than 7 LEG/ml, and serum ALT level was more than 100 IU/L, HBV genotype was B. IFN and LMV were the similar effect on response (P = 0.410). On IFN therapy, cumulative rate of response in patients of <35 years was higher than that in patients > or =35 years (P = 0.002). Our results suggest that (1) IFN and LMV are the similar effect on response, (2) IFN therapy is more effective for younger patients. 相似文献
6.
Hepatic histology of patients with HIV infection and chronic hepatitis C treated with interferon.
下载免费PDF全文
![点击此处可从《Journal of clinical pathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
R Boldorini P Vigan G Monga M Nebuloni A Cargnel G Gubertini G Migliaretti G Costanzi 《Journal of clinical pathology》1997,50(9):735-740
AIMS: To evaluate the histological changes seen in liver biopsies after interferon (IFN) treatment in patients with chronic hepatitis C and human immunodeficiency virus (HIV) infection. METHODS: Twenty four intravenous drug users with chronic hepatitis C were investigated histologically before beginning a 12 month course of IFN treatment and 18 months later. Twelve were HIV positive, without opportunistic or other viral infections (group A), and 12 were HIV negative (group B). RESULTS: According to alanine amino-transferase concentrations, four sustained responders and eight non-responders were found in group A; six sustained responders, five relapsers, and one non-responder were found in group B. HCV RNA became negative in one sustained responder of group A and in the six sustained responders of group B. When histological findings of biopsies performed before therapy and 18 months later were compared, no significant changes in the mean value of Knodell's index and subindices were found in group A, whereas in group B Knodell's index, piecemeal necrosis, and focal hepatocellular necrosis decreased significantly. CONCLUSIONS: In chronic hepatitis C, coinfection with HIV showed a tendency towards a lower response to IFN, although this did not reach statistical significance; however, none of the HIV positive patients developed cirrhosis during the follow up and this should be considered in clinical management of such patients. 相似文献
7.
Characterization of antigen moiety of HBsAg in the complement fixing immune complexes of hepatitis B virus positive chronic active hepatitis.
下载免费PDF全文
![点击此处可从《Clinical and experimental immunology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
R C Gupta 《Clinical and experimental immunology》1982,49(3):543-551
Circulating immune complexes (CIC) are frequently found in hepatitis B virus-induced chronic active hepatitis. Since antigen and antibody moieties of complexes are critical in determining many of its pathogenic factors, the constituents of these complexes were investigated with particular attention to the quantity and nature of the HBs antigen moiety of the complexes. Complement fixing immune complexes were isolated from sera of 14 patients with chronic active hepatitis by utilizing conglutinin's unique property to bind C3-fixed complexes. Low pH (2.6) was used to dissociate the complexes. Components of dissociated complexes were separated into antigen and antibody fractions using immobilized Protein A. Both fractions were analysed by electrophoresis in polyacrylamide gel with SDS. The antibody fractions showed heavy and light chains of IgG and IgM. The antigen fractions demonstrated six to 10 protein bands with mol. wt ranging between 17,000 and 120,000 daltons. To define precisely the polypeptide antigen moiety involved in the immune complex formation, a transfer blotting technique was used employing human anti-HBs globulin as probe. Polypeptides with mol. wt 97,000 and 49,000 reacted as antigen moieties of HBsAg. In addition, the levels of HBsAg in the antigen fractions were significantly greater (P less than 0.005) compared to sera from patients with acute hepatitis. Implications of these findings are discussed. 相似文献
8.
9.
Marion Levast Sylvie Larrat Marie‐Ange Thelu Sandrine Nicod Agnès Plages Alice Cheveau Jean‐Pierre Zarski Jean‐Marie Seigneurin Patrice Morand Vincent Leroy 《Journal of medical virology》2010,82(5):747-754
The prevalence of occult hepatitis B, defined by absence of HBsAg and HBV DNA, ranges widely in patients with hepatitis C. This may influence the treatment of hepatitis C and the severity of liver disease. Sensitive and specific real‐time PCR techniques are available commercially and can detect more reliably low HBV DNA levels. The aim of this study was to determine the prevalence of occult hepatitis B virus infection using the COBAS Taqman assay (Roche Diagnostics, Meylan, France) in the serum and liver of HBsAg negative patients with chronic hepatitis C and to evaluate its clinical consequences on liver pathology and its impact on the response to treatment with peg‐IFNα and Ribavirin. HBV DNA detection was assessed retrospectively on 140 sera and 113 liver biopsies of HCV positive/HBsAg negative patients before treatment. A 4.4% (5/113) prevalence of occult hepatitis B was recorded in liver samples and in none of the sera. Anti‐HBc was not detected in one, three of whom were sustained virological responders to treatment, one was relapsed responder and one was non‐responder. Furthermore, in this cohort composed of 12% anti‐HBs negative/anti‐HBc positive and 20% anti‐HBs positive/anti‐HBc positive patients, anti‐HBc was not associated with pre‐therapeutic viral load, ALT serum levels, and histological activity or fibrosis. Using a commercial real‐time PCR assay, we observed a low prevalence of occult B hepatitis. This, just as anti‐HBC status, had no clinical impact in a large cohort of hepatitis C patients. It therefore does not appear useful to screen for occult hepatitis B in these patients with this test before beginning HCV treatment. J. Med. Virol. 82: 000–000, 2010. © 2010 Wiley‐Liss, Inc. J. Med. Virol. 82: 747–754, 2010. © 2010 Wiley‐Liss, Inc. 相似文献
10.
Hepatitis B vaccination in patients with chronic hepatitis C. 总被引:4,自引:0,他引:4
The aim of the study was to evaluate the safety, immunogenicity, and possible therapeutic effect of hepatitis B vaccine in patients with chronic hepatitis C. The subjects studied included three groups: group I, 26 patients with chronic hepatitis C who were susceptible to hepatitis B virus infection; group II, 35 healthy subjects who were susceptible to both hepatitis B and hepatitis C virus infection; and group III, 30 patients with chronic hepatitis C receiving no hepatitis B vaccination as controls. Three 20 microg/dose of recombinant hepatitis B vaccines were given to subjects of groups I and II in months 0, 1, and 6. Blood samples from the subjects were collected before and 1 month after each dose of vaccination for serological testing. The subjects of groups I and II had similar antibody to hepatitis B surface antigen (anti-HBs) response rates after the first (30.8% vs. 17.1%), second (61.5% vs. 60.0%), and third (88.5% vs. 91.4%) doses of vaccination. Also, their geometric mean titers of anti-HBs did not differ much when vaccination completed in 7 months (360 vs. 581 mIU/ml). During vaccination period, patients with chronic hepatitis C demonstrated no significant change of serum cytokines and HCV RNA levels, but significantly lowered ALT levels after three doses of vaccination. Hepatitis B vaccination is safe and immunogenic in patients with chronic hepatitis C. It did not significantly affect their levels of HCV RNA, but tended to lower ALT levels. 相似文献
11.
M. Basaras B. de las Heras M. García Bengoechea L. Gallego E. Arrese R. Cisterna 《European journal of clinical microbiology & infectious diseases》1996,15(11):887-890
PCR was used to detect hepatitis C virus (HCV) RNA in serum and peripheral blood mononuclear cells (PBMCs) for evaluation of a six-month course of Interferon therapy in 18 patients with histologically confirmed chronic hepatitis C. At follow-up six months after the end of therapy positive-stranded (genomic) and negative-stranded (anti-genomic, presumptive replicative intermediate) HCV RNA could be detected in PBMCs of all ten patients who either did not respond to therapy or suffered a relapse; genomic strand RNA was detected in five patients who responded but then relapsed. The study confirms that interferon therapy leads to inhibition of HCV replication but not eradication of the virus. Persistence of the virus at extrahepatic sites may explain its reactivation after cessation of interferon therapy. 相似文献
12.
Seventy five patients with acute and chronic active hepatitis (CAH) were studied by indirect immunofluorescence with monoclonal antibodies for the presence of hepatitis B surface antigen (HBsAg) on peripheral blood mononuclear cells (PBMC). The viral surface antigen was detected in the PBMC of all the patients with hepatitis B virus (HBV)-induced CAH and in acute patients with more than 2 months of evolution. No HBsAg was detected in the samples obtained from 12 normal controls or from 14 non-A, non-B CAH patients. Analysis of PBMC subsets revealed that HBsAg was present in non-T cells; dual fluorescence studies showed HBsAg on surface Ig-positive lymphocytes. The binding of anti-HBs monoclonal antibodies was higher than that of a goat anti-HBs serum, and the highest reactivity was observed with an antibody against the pre-S(2)-region sequence. Both HBsAg and hepatitis B core antigen (HBcAg) were also detected in lysates of PBMC by dot blot analysis. 相似文献
13.
目的研究基因1型慢性丙型肝炎(CHC)患者治疗过程中外周血自然调节性T细胞(nTreg)的动态变化及其与抗病毒疗效的关系。方法32例初治的CHC患者,均为基因1型,治疗方案为干扰素联合利巴韦林治疗48周。分别在治疗前、治疗过程中2、4、8、12、24、48周以及治疗结束后12或24周采集外周血标本。用流式的方法检测外周血单个核细胞(PBMC)中nTreg的比率。COBASAmpliprep/COBAS TaqmanHCV试剂盒检测HCV—RNA定量。结果24例患者治疗12周时HCV—RNA转阴,并且随访至治疗结束后24周仍阴性,达到持续病毒学应答(SVR);8例患者治疗12周时病毒量未转阴,无应答(NVR),24周时终止治疗。应答组和无应答组治疗前外周血中nTreg的比率差异无统计学意义(P〉0.05)。应答组治疗过程中2、4、12、24、48周及治疗结束后各个时间点PBMC中nTreg水平分别为(0.91±0.22)%、(1.31±0.29)%、(1.78±0.43)%、(1.92±0.44)%、(1.90±0.37)%、(1.14±0.35)%;在治疗2周(P〈0.001)及治疗结束后(P〈0.001)下降明显。无应答组治疗过程中2、4、12、24周及治疗结束后各时间点PBMC中nTreg水平分别为(1.21±0.15)%、(1.24±0.18)%、(1.42±0.11)%、(1.45±0.11)%、(1.14±0.10)%;Treg水平在治疗4周时缓慢上升(P=O.005),在治疗结束后显著下降,与治疗24周比较差异有统计学意义(P〈0.001)。结论CHC患者外周血nTreg水平与干扰素/N巴韦林抗病毒治疗的疗效密切相关,抗病毒治疗2周时nTreg水平的下降可以预测其疗效。提示nTreg可能在机体清除病毒的早期过程中起着重要作用。 相似文献
14.
Sang Bun Choi Youn Jae Lee Jae Ik Lee Young Jin Song Byoung Jin Choi Jong Han Kim Eun Uk Jung Sung Jae Park Sang Heon Lee Ji Hyun Kim Jung Sik Choi Sam Ryong Jee Sang Yong Seol 《Clinical and molecular hepatology》2011,17(3):183-188
Background/Aims
The reappearance rates of hepatitis C virus (HCV) RNA after a sustained virological response (SVR) have been reported to be 1-2%. We investigated the reappearance rate of HCV RNA after SVR in chronic hepatitis C (CHC) patients treated with pegylated interferon (PEG-IFN) and ribavirin.Methods
In total, 292 CHC patients who achieved an SVR after PEG-IFN and ribavirin treatment were included. They were treated with subcutaneous injections of either PEG-IFN-α 2a or 2b plus ribavirin orally. Liver function tests and qualitative HCV RNA assays were performed every 6 months during the follow-up period after an SVR.Results
Among the 292 patients, 224 (genotype 1, 92; genotype non-1, 132) were followed up for more than 6 months after SVR. These 224 patients were aged 48.1±11.5 years (mean±SD), and 129 of them were male. The median follow-up duration was 18 months (range 6-60 months). The reappearance rate of HCV RNA during follow-up was 0%. Two patients who achieved an SVR developed hepatocellular carcinoma during the follow-up period.Conclusions
An SVR was maintained in all CHC patients treated with PEG-IFN plus ribavirin during a median follow-up of 18 months. However, a screening test for hepatocellular carcinoma is needed for patients with an SVR. 相似文献15.
S. Zhao E. Liu K. Wei Y. Wang Y. Li B. Huang Y. Chen P. Yang 《European journal of clinical microbiology & infectious diseases》2011,30(1):51-57
Higher sustained virological response (SVR) rates after treating with peginterferon than after treating with interferon have
been obtained in some randomized clinical trials (RCTs) in Chinese patients with chronic hepatitis C (CHC). However, the numbers
of patients included in these clinical trials were too small to draw a clear conclusion. Therefore, a new meta-analysis including
a large number of patients was needed to compare peginterferon with interferon in the treatment of Chinese CHC patients. A
search of Medline, the China National Knowledge Infrastructure, the Wanfang Database, and the China Biomedical Database for
relevant articles published between 1966 and 2009 was performed. RCTs comparing the use of peginterferon and interferon for
the treatment of Chinese patients with CHC were assessed. Of the 236 studies screened, 18 RCTs including 1,148 patients (659
treated with peginterferon therapy and 489 treated with interferon therapy) were analyzed. The total SVR rates obtained in
patients treated with peginterferon were significantly higher than those obtained in patients treated with interferon (64%
vs. 40%; relative risk, 1.56; 95% confidence interval: 1.28–1.91; p < 0.01), but the difference between the peginterferon α-2b and interferon α-2b treatments was not significant. Withdrawal
rates were similar between patients treated with peginterferon and interferon. Chinese patients with CHC have a greater likelihood
of achieving an SVR with peginterferon α-2a. 相似文献
16.
17.
Jeong Han Kim Yun Jung Choi Hee Won Moon Soon Young Ko Won Hyeok Choe So Young Kwon 《Clinical and molecular hepatology》2013,19(4):409-416
Background/Aims
Quantification of the hepatitis B surface antigen (HBsAg) is increasingly used to determine the treatment response in patients with chronic hepatitis B (CHB). However, there are limited data about the clinical implications of Quantification of HBsAg long-term nucleoside analogue treatment for CHB. We investigated the clinical correlation between HBsAg level and clinical course in patients with CHB who are treated long-term with nucleoside analogues.Methods
Patients with CHB who started lamivudine or entecavir monotherapy before June 2007 were enrolled. HBsAg was quantified at baseline, at 6 months, and at 1, 2, 3, 4, and 5 years of treatment. We compared data between the groups according to the presence or absence of a virological response (VR) and resistance.Results
Forty-eight patients were analyzed. There was no definite reduction in HBsAg level during the early period of treatment; differences in HBsAg levels between baseline and each time point were significant only at 5 years (P=0.028). In a subgroup analysis, this difference was significant only in non-resistant patients at 5 years (P=0.041).Conclusions
There was no definite decrease in the HBsAg level during the early period of nucleoside analogue treatment, with long-term treatment being required to observe a significant reduction. 相似文献18.
Various scoring systems evaluating histologic features of chronic hepatitis C treated with interferon 总被引:1,自引:0,他引:1
Ikawa H Hayashi Y Ninomiya T Yano Y Nakaji M Nagano H Seo Y Kumon Y Yoon S Kasuga M Itoh H Ohbayashi C 《Human pathology》2001,32(9):910-917
Various scoring systems for chronic hepatitis have been proposed; however, there is no standard scoring system for studies of interferon (IFN) therapy in patients with chronic hepatitis C. The aims of this study were to determine the most useful system reflecting histologic changes in biopsy specimens from complete responders and predicting the efficacy of IFN therapy. Patients with chronic hepatitis C were administered IFN-alpha for 6 months. Forty-six patients were included in this study and categorized as complete responders (n = 15), partial responders (n = 24), and nonresponders (n = 7) according to viral and biochemical responses to the therapy. Biopsy specimens obtained from each patient before and after treatment were evaluated under 3 different systems: Histological Activity Index (HAI), modified HAI, and Scheuer classification. Complete responders showed considerable improvement in both grade and stage on the modified HAI and Scheuer classifications. On the HAI, a considerable improvement was observed in grade but not in stage. No significant change was observed in partial responders or nonresponders on any system. Prediction of complete response was not possible under any system, but the pretreatment score reflecting piecemeal necrosis on any 1 of the 3 classifications and the fibrosis score on Scheuer classification were predictors of nonresponse. The modified HAI system and Scheuer classification were amply useful in evaluating histologic changes in complete responders. Scores higher than 4 of the categories reflecting piecemeal necrosis on any system and fibrosis scores of 3 or 4 on Scheuer classification predicted nonresponse to IFN therapy. 相似文献
19.
Changes in serum and red blood cell membrane lipids in patients treated with interferon ribavirin for chronic hepatitis C 总被引:2,自引:0,他引:2
Abstract One of the side effects by interferon ribavirin (I/R) treatment is haemolytic anemia, causing some patients to discontinue
I/R treatment. The exact mechanism of I/R-induced anemia is unknown. The aim of this study is to evaluate the effects of I/R
treatment on the serum lipid and red blood cell (RBC) membrane lipid profiles of patients with chronic hepatitis C (CHC) and
the association between changes of RBC membrane lipids and haemolytic anemia by I/R treatment. Fourteen patients with CHC
were treated with I/R and their serum lipid profiles were studied. In addition, in seven of the 14 patients, the RBC membrane
lipid profiles were analysed. In the RBC membrane lipid composition, the total cholesterol, total phospholipids and cholesterol/phospholipids
(C/PL) ratio were significantly increased. Phosphatidylcholine (PC) and the phosphatidylcholine/ sphingomyelin (PC/SM) ratio
were significantly decreased and other phospholipid fractions were significantly increased. Changes in the serum lipids and
RBC membrane lipid profiles of patients with CHC treated with I/R were shown. Especially, a decrease in the RBC deformability
and membrane fluidity by changes in these RBC membrane lipids was supposed and it is suggested that those changes may result
in haemolytic anemia by I/R treatment. 相似文献
20.
A Nonomura M Tanino H Kurumaya G Ohta Y Kato K Kobayashi 《Clinical and experimental immunology》1982,47(3):595-605
Peripheral T lymphocytes from patients with chronic active hepatitis (CAH) showed a significantly decreased suppressor cell (or increased helper cell) effect on differentiation of allogenic B cells to Ig-producing cells (Ig-PC). Spontaneous helper cell activity as measured after irradiation of T cells appeared normal, while Concanavalin A (Con A)-induced suppressor cell activity was significantly reduced. Some patients of chronic persistent hepatitis (CPH) also showed mild depression of Con A-induced suppressor cell activity. Poor suppressor cell activity in CAH was much more often seen in HBsAg negative, autoantibody positive patients than in HBsAg positive autoantibody negative ones. Autologous mixed lymphocyte reaction (AMLR) was significantly decreased in patients with CAH. Also, a serum factor(s) that decreased Con A-induced suppressor cell function of healthy subjects could be demonstrated in some patients with CAH and CPH. Our results suggest that altered immune responses observed in CAH may be due to defective suppressor cell function, partly attributable to serum factor(s). 相似文献